ストックスクリーナーアプリを入手
586.48
0.80%
-4.72
アフターアワーズ：
586.48
United Therapeutics Corp (UTHR) 最新ニュース
Options exercised at $117.76 a share accompanied sales by United Therapeutics (UTHR) CEO's trusts. - Stock Titan
$100 Invested In United Therapeutics 15 Years Ago Would Be Worth This Much Today - Benzinga
United Therapeutics Rising Ahead of Next Earnings Report - FXEmpire
FDA clears United Therapeutics to begin Treprostinil-Iloprost trial - StreetInsider
CEO trusts exercised $117.76 options and sold 9,500 shares in United Therapeutics (UTHR). - Stock Titan
S&P 500 Futures Up in Premarket Trading; MSG Sports, United Therapeutics Lag - Barron's
United Therapeutics CEO sells $5.5M in stock By Investing.com - Investing.com Nigeria
Form 4 United Therapeutics Corporation: Martine A. Rothblatt (Director, Chairperson & CEO) For: 23 October - Investing.com Nigeria
United Therapeutics CEO sells $5.5M in stock - Investing.com
After exercising options at $117.76, United Therapeutics (UTHR) CEO trusts sell 9,500 shares. - Stock Titan
United Therapeutics (NDQ:UNTR): The Only Company Attempting Xenotransplantation At Scale! - Stocks Down Under
U.S. transgender billionaire Martine Rothblatt sells $5.5 million in United Therapeutics stock - Billionaires.Africa
Martine Rothblatt, United Therapeutics CEO, sells $5.5M in stock - Investing.com
United Therapeutics Gets FDA Clearance to Start Phase 2 SUMMIT Trial of Treprostinil Soft Mist Inhaler in PH-COPD - BioBuzz
United Therapeutics to build a $9 million hangar at Rochester's airport - Post Bulletin
United Therapeutics CEO Rothblatt sells $5.3m in UTHR stock - Investing.com
Is United Therapeutics Corp (UTHR) Overvalued After 3.8% Rally? - GuruFocus
Generation Park lands new facility to scale xeno-organ production - InnovationMap
United Therapeutics authorizes $2 billion buyback program - Investing.com
United Therapeutics Authorizes Up to $2 Billion Share Repurchase - TradingView
United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization - Yahoo Finance
United Therapeutics CEO Martine Rothblatt sells $5.26m in stock - Investing.com
CEO trusts sell 9,500 United Therapeutics (UTHR) shares after exercising stock options. - Stock Titan
United Therapeutics Corporation to Report Third Quarter 2026 Financial Results Before Market Open on Wednesday, November 4, 2026 - Yahoo Finance
Form 4 United Therapeutics Corporation: Martine A. Rothblatt (Director, Chairperson & CEO) For: 19 October - Investing.com Nigeria
United Therapeutics CEO Rothblatt sells $5.16m in shares - Investing.com
United Therapeutics (UTHR): Can the Profit-Machine Biotech Finally Crack the S&P 500? - Yahoo Finance
United Therapeutics opens third xenograft production facility - Investing.com
A Houston site is built to make pig kidneys and hearts for United Therapeutics’ organ program. - Stock Titan
United Therapeutics opens xeno-organ facility in Generation Park, marking Houston's continued pharma growth - The Business Journals
United Therapeutics Expands Organ Manufacturing Capabilities with Opening of Third Designated Pathogen-Free Xenograft Production Facility - Yahoo Finance
United Therapeutics chairperson & CEO sells $5.08m in shares By Investing.com - Investing.com Nigeria
Form 4 United Therapeutics Corporation: Martine A. Rothblatt (Director, Chairperson & CEO) For: 16 October - Investing.com Nigeria
After exercising options at $117.76, CEO trust sells 9,500 United Therapeutics (UTHR) shares. - Stock Titan
Here’s How Much You Would Have Made Owning United Therapeutics Stock In The Last 5 Years - Benzinga
Here’s How Much You Would Have Made Owning United Therapeutics Stock In The Last 5 Years - Benzinga
United Therapeutics (UTHR) Gains FDA Approval for SUMMIT Trial o - GuruFocus
Up to 800,000 people have high blood pressure in the lungs linked to chronic lung disease. An inhaler trial can proceed. - Stock Titan
United Therapeutics (NASDAQ:UTHR): A GARP Case Built on Durable Growth at a Reasonable Price - ChartMill
United Therapeutics chairperson & CEO sells $5.19m in stock - Investing.com
Paul Mahon, United Therapeutics EVP, sells $4.5m in stock - Investing.com
After exercising options at $117.76 each, CEO trust sells 9,500 United Therapeutics (UTHR) shares. - Stock Titan
An 8,300-share planned sale follows an option exercise by United Therapeutics (UTHR) counsel. - Stock Titan
United Therapeutics CEO Rothblatt sells $5.1m in shares By Investing.com - Investing.com Nigeria
After exercising options at $117.76, United Therapeutics (UTHR) CEO family trusts sell 9,500 shares. - Stock Titan
A CEO trust exercises options at $117.76 and sells 9,500 United Therapeutics (UTHR) shares. - Stock Titan
United Therapeutics secures $381M settlement in patent dispute with competitor - The Business Journals
LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label - Zacks Investment Research
Liquidia shares surge 25% as settlement ends United Therapeutics litigation - Yahoo Finance
SGIOY or UTHR: Which Is the Better Value Stock Right Now? - Zacks Investment Research
0.27%
0.55%
大文字化:
|
ボリューム (24 時間):